ArticleScientific reports2025
Prediction of recurrence after resection in hepatocellular carcinoma via whole liver deep learning on preoperative contrast-enhanced CT.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
This study aimed to develop a fully automated survival prediction (FASP) system that analyzes whole-liver regions from preoperative contrast-enhanced CT scans for predicting recurrence-free survival (RFS) after curative resection in Hepatocellular carcinoma (HCC). FASP comprised three consecutive components: automatic liver and tumor segmentation models, and a RFS prediction model, LiverSurv, all based on deep convolutional neural networks. FASP was compared against a clinical model leveraging clinical factors and three tumor-based methods using semantic, radiomic, or deep learning features. A total of 827 patients were included across the development, internal test, and external test sets. In the internal and external test sets, FASP achieved concordance indices (C-indices) of 0.646 (95% CI: 0.566, 0.725) and 0.786 (95% CI: 0.726, 0.846), respectively, outperforming the clinical model (both adjusted P<.05). Integrating clinical factors improved C-indices to 0.664 (95% CI: 0.591, 0.736) internally and 0.800 (95% CI: 0.750, 0.849) externally. FASP also surpassed the tumor-based models, which yielded C-indices ranging from 0.623 to 0.632 internally and 0.523 to 0.775 externally. Visualization analysis demonstrated that FASP captured prognostic information from both tumor and background liver regions. These findings suggest whole-liver-based deep learning provides a promising non-invasive approach to predict recurrence risk for HCC patients before surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.